What does the future of COA's look like?
This week's guests John Fox & Olivier Wong deep-dive into the digital and tech landscape, alongside evidence quality barriers, alternate viewpoints, and the importance of a patient-centric process to payers and regulators.
From complexity to variety, how do PRO measures affect the day-to-day of clinical practice?
Experts Ethan Basch and Norah Crossnohere are here to explain – all while evaluating the landscape of current practice, how it helps patient and providers, and potential future process adjustments.
In this week's episode, Matt is joined by Mel Calvert and Hilary Jones to discuss how to choose the right digital COA measures in clinical research. In particular, what do we want to measure in the trial, why do we want to measure it, and what needs consideration to minimize the risk of missing data?
How do we specify clinical outcome assessment endpoints?
In this COA in PROgress podcast episode John Powers and Cheryl Coon offer insight into how to frame an endpoint that contains clinical outcome assessment data.
Patient-reported outcome measures – are there too many or too few?
Professors Michael Brundage and David Cella debate this question and deep-dive into a few patient prioritization measures on this week's all-new episode, including the criteria for validity, reliability, and scoring interpretability.
How do you create a good end-to-end patient centered drug development strategy?
Join Sonya Eremenco and John Powers as they discuss why it's important to put patients at the heart of COA approaches – from concept to endpoint positioning, and the most crucial steps in between.
This week, we're putting the PRO in PROgress by discussing Patient Reported Outcomes with guests Paul Miller and Olivier Wong. In particular, how they're shaping the world of health technology assessment.
From introduction to interpretation, join Dan O’Connor and Chad Gwaltney as they explore how best to meet the expectations of regulatory authorities. Including: demystifying COA guidance documents and discussing how they became an integral part of the regulatory landscape.